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Statins, which are used as cholesterol-lowering agents,
have anti-inflammatory and immune-regulating proper-
ties. Little comprehensive analysis has been made to
investigate the impact of statins on human T lympho-
cytes function, their proliferation and production of Th1
and Th2 cytokines. We also investigated if the immu-
nossupresive effects of statins are due to their impact on
human T lymphocytes or proffesional antigen-presenting
dendritic cells (DC) alone, or both.
Human peripheral blood mononuclear cells (MNC)
proliferation was induced with phytohemagglutinin.
Immature DC were cultivated from monocytes of
healthy donors. DC maturation was induced by lipopoly-
saccharide (LPS; 1 μg/mL). Unstimulated and LPS-sti-
mulated DC were treated with atorvastatin (1-10 μM).
Ability to induce T cell proliferation and the secretion
of cytokines were performed in mixed leukocyte
reaction.
Atorvastatin reduced phytohemagglutinin-stimulated
MNC proliferation, dose dependently. The results
showed that atorvastatin, only in high concentrations,
strongly inhibit allogenic lymphocytes proliferation irre-
spectively which stimulators are used: immature or
mature dendritic cells. Low concentrations of atorvasta-
tin even stimulated proliferation when the immature
dendritic cells were used as stimulators. Atorvastatin
have influence on DC differentiation and maturation by
changing expression and mean fluorescence intensity of
costimulatory, adhesive and maturation molecules such
as HLA-DR, CD80, CD83, CD86, CD40, CD54 and
CD25. Atorvastatin affects allostimulatory activity of
both immature and mature MoDC but in completely
oposite way, using different DC/Ly ratio, and change
production of TNF-a by immature DC and IL-18 by
mature DC and not affect IL-10 and IL-12 production.
Atorvastatin decreased the level of IFN-g, increase the
level of IL-10, and not affected the level of IL-4 in DC
culture supernatants when the atorvastatin was added
during maturation. If the atorvastatin was added in
monocite culture, no significant change in cytokine level
was observed.
Our data provide strong evidence that atorvastatin can
act as an immunomodulator by reducing, but in low
dosage stimulating T lymphocite proliferation, inhibiting
the immune response of Th1, decreasing the expression
of co-stimulatory molecules, and changing DC cytokine
secretion, which can help in better understanding how
to take advantage of these new mechanistic insights in
increased use of statins in therapeutic strategy in differ-
ent immune/inflamatory disorders in future.
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